INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 155 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $1,432 | +96.4% | 20 | +42.9% | 0.00% | – |
| Q3 2023 | $729 | -49.9% | 14 | -39.1% | 0.00% | – |
| Q2 2023 | $1,456 | +92.1% | 23 | +64.3% | 0.00% | – |
| Q1 2023 | $758 | +2.3% | 14 | 0.0% | 0.00% | – |
| Q4 2022 | $741 | -25.9% | 14 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 14 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 14 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | 0.0% | 14 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 14 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 14 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | – | 14 | 0.0% | 0.00% | – |
| Q1 2021 | $0 | – | 14 | 0.0% | 0.00% | – |
| Q4 2020 | $0 | – | 14 | 0.0% | 0.00% | – |
| Q3 2020 | $0 | – | 14 | 0.0% | 0.00% | – |
| Q2 2020 | $0 | – | 14 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 14 | – | 0.00% | – |
| Q2 2017 | $0 | – | 0 | -100.0% | 0.00% | – |
| Q1 2017 | $0 | – | 19 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |